Company Performance Metrics
Onur Boyman: Co-Founder and Director- Jonathan Sprent: Co-Founder and Director
Nascent Biotech is a biotechnology company building a portfolio of innovative therapeutic antibodies. The innate ability of the intelligence of the natural human immune system to generate a cancer-specific response combined with NBI’s technical skills opens the door for immunologically based therapeutics for human cancer. NBI is using and
developing human antibodies and cytokine responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization.
Nascent Biotech's technology portfolio is based upon the natural human immune system, uniquely utilizing the immune system’s innate capabilities and selectivity to produce effective immune-boosting and regulation biomolecules. Their insight into the natural human immune response defines important targets for therapeutic intervention thus enabling the rapid development of new classes of safe, non-toxic, and specific biological drugs for use in the clinic.
